The Medicines Manufacturing Innovation Centre: Two Years On

In 2019, we announced two “Grand Challenges” (and our grand ambitions) to the world. Where are we now?

Dave Tudor | 03/08/2021 | Quick Read

Almost two years into the Medicines Manufacturing Innovation Centre collaboration, we have seen new advanced technology, new partners, and a new state-of-the-art facility, which recently broke ground in Scotland. These innovative advancements have been enabled by our ever-growing network of multi-disciplinary partners, who are working together to drive medicines manufacturing forward. This partnership model allows us to reduce waste, increase speed, and lower costs.

The adoption of advanced technology into pharmaceutical manufacturing is challenging; it can be time-consuming, costly, and risky for companies. This collaboration allows us to de-risk the process for our partners, whilst enabling the introduction of new technology into this sector. I am overjoyed with the updates we are now seeing from Grand Challenge 1 and 2, and we are pleased to announce the start of work on Grand Challenge 3, which focuses on improving the way we currently manufacture oligonucleotides. Over the coming months and years, we will continue to introduce new Grand Challenges and other programs to further address the critical challenges facing the pharma industry.

This interview delves deeper into Grand Challenges 1 and 2 – and the overall mission.

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Manufacture Small Molecules, Facilities

Dave Tudor

Managing Director of the Medicines Manufacturing Innovation Centre, Quality and Biologics, at CPI